Image ORIGINAL



PTO/SB/H7 (10-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FEE TRANSM for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

Under the Paperwork Reduction Act of 1995,

(\$) 180.00

spond to a conection of find	intialion unless it displays a valid Olvib control humber
Co	omplete if Known
Application Number	09/965,708
Filing Date	September 26, 2001
First Named Inventor	Markus Heil
Examiner Name	Sonya N. Wright
Art Unit	1626
Attorney Docket No.	LeA 34 813

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)						
Check Credit card Money Other None	e 3. ADDITIONAL FEES						
Deposit Account:	Large Entity Sma	III Entity					
Danasit		Fee Fee Description					
Deposit Account 13-3372	Code (\$) Code 1051 130 2051	• • • • • • • • • • • • • • • • • • • •	ee Paid				
Number Deposit		-					
Account Jeffrey M. Greenman	1052 50 2052	2 25 Surcharge - late provisional filing fee or cover sheet					
Name The Director is authorized to: (check all that apply)	1053 130 1053	3 130 Non-English specification					
Charge fee(s) indicated below Credit any overpayments	1812 2,520 1812	2,520 For filing a request for ex parte reexamination					
Charge any additional fee(s) or any underpayment of fee(s)	1804 920* 1804	4 920* Requesting publication of SIR prior to Examiner action					
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805 1,840* 1805	5 1,840* Requesting publication of SIR after Examiner action					
	1251 110 2251	1 55 Extension for reply within first month					
FEE CALCULATION 1. BASIC FILING FEE	1252 420 2252						
1. BASIC FILING FEE Large Entity Small Entity	1253 950 2253	3 475 Extension for reply within third month					
Fee Fee Fee Fee Description Fee Paid	1254 1,480 2254	4 740 Extension for reply within fourth month					
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee 1770 00 1	1255 2,010 2255	5 1,005 Extension for reply within fifth month					
1002 340 2002 170 Design filing fee 770.00	1401 330 240	of Appeal					
1003 530 2003 265 Plant filing fee	1402 330 240	2 165 Filing a brief in support of an appeal					
1004 770 2004 385 Reissue filing fee	1403 290 240	3 145 Request for oral hearing					
1005 160 2005 80 Provisional filing fee	1451 1,510 1451	1 1,510 Petition to institute a public use proceeding					
SUBTOTAL (1) (\$)	1452 110 245	52 55 Petition to revive - unavoidable					
	1453 1,330 2453	3 665 Petition to revive - unintentional					
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501 1,330 2501	1 665 Utility issue fee (or reissue)					
Extra Claims below Fee Paid	1502 480 250	2 240 Design issue fee					
Total Claims	1503 640 250	3 320 Plant issue fee					
Claims Multiple Dependent	1460 130 146	130 Petitions to the Commissioner					
	1807 50 180						
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1806 180 180	bo 100 outsinission of information bisclosure outsi	80.00				
Code (\$) Code (\$)	8021 40 802	21 40 Recording each patent assignment per property (times number of properties)					
1202 18 2202 9 Claims in excess of 20	1809 770 280	09 385 Filing a submission after final rejection					
1201 86 2201 43 Independent claims in excess of 3		(37 ČFR 1.129(a))					
1203 290 2203 145 Multiple dependent claim, if not paid	1810 770 281	10 385 For each additional invention to be examined (37 CFR 1.129(b))					
1204 86 2204 43 ** Reissue independent claims over original patent	1801 770 2801	•					
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802 900 1802	, , ,					
	Other fee (specify)	* ''					
SUBTOTAL (2) (\$)	*Reduced by Basic) 1				
**or number previously paid, if greater; For Reissues, see above		(Ψ)					

SUBMITTED BY			(Complete	(if applicable))
Name (Print/Type)	Susan M. Pellegrino	Registration No. 48,972	Telephone	(203) 812-6450
Signature	Susan M. Lellan	no	Date	01/16/2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Markus Heil, et al.

Serial No.: 09/965,708

Group Art Unit: 1626

Filed: September 26, 2001

Examiner: Sonya N. Wright

For: PHENOXYPHENYL ALKANESULPHONATES

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 16, 2004

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

- 1. The information disclosure statement transmitted herewith is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either
 - (1) a final action under section 1.113 or
 - (2) a notice of allowance under section 1.311

whichever occurs first.

FEE

2. Accompanying this transmittal is the fee for submission of an information disclosure statement under § 1.97(c). (\$180.00)

01/26/2004 EHAILE1 00000069 133372 09965708

01 FC:1806

180.00 DA

FEE PAYMENT

3. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

METHOD OF PAYMENT OF FEE

4. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

January 16, 2004

 Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516-4175

Telephone: (203) 812-6450 Facsimile: (203) 812-6459

Susan M. Pellegrino / Attorney for Applicants

Reg. No. 48,972

U.S. PATENT DOCUMENTS													
*				DOCUMENT NO.			DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE		

	• FOREIGN PATENT DOCUMENTS													
				DOCU	IMEN	IT NO	DATE COLINTRY	COUNTRY	PRIMARY	SUB-	TRANSLATION			
							•	,	DD/MM/YY		CLASS	CLASS	YES	NO
	 												_	
										1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
L			1											1

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)
R1	Consroe, Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders, Neurobiol. Disease, 5:534-551, 1998
R2	Williamson, et al., Cannabinoids in Clinical Practice, Drugs 60:1303-1314, 2000
R3	Drysdale, et al., Cannabinoids: Mechanisms and Therapeutic Applications in the CNS, Curr. Med. Chem. 10:2719-2732, 2003

EXAMINER	DATE CONSIDERED
----------	-----------------

^{*} EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.